Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen 2Q

Total product sales for the quarter were $3.6 billion (-1%). Sales in the U.S. totaled $2.8 billion (-2%) and International sales were up 3% to $826 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 2Q

2Q Revenues: $3.8 billion (+3%)

2Q Earnings: $1.2 billion (-5%)

YTD Revenues: $7.4 billion (+6%)

YTD Earnings: $2.4 billion (+4%)

Comments: Total product sales for the quarter were $3.6 billion (-1%). Sales in the U.S. totaled $2.8 billion (-2%) and International sales were up 3% to $826 million. U.S. product sales in the quarter include a $45 million unfavorable impact for certain U.S. Health Care Reform Legislation provisions. Worldwide sales of Aranesp were down 13% to $603 million due to decline in demand. Sales of Epogen were $657 million (+3%). Combined worldwide sales of Neulasta and Neupogen were up 1% to $1.2 billion in the quarter. Sales of Enbrel were $877 million (-2%). Worldwide sales of Sensipar were $172 million (+3%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters